Empowered Funds LLC Acquires Shares of 43,120 Edwards Lifesciences Corporation $EW

Posted by Brenda Bartman on Sep 2nd, 2026

Empowered Funds LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 43,120 shares of the medical research company’s stock, valued at approximately $3,901,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. TrinityBridge Ltd purchased a new stake in Edwards Lifesciences during the second quarter worth about $27,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $26,000. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at approximately $25,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $27,000. Finally, JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. UBS Group initiated coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target on the stock. Evercore reiterated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Check Out Our Latest Analysis on EW

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $90.78 on Wednesday. The firm has a market capitalization of $52.27 billion, a P/E ratio of 52.17, a PEG ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The business has a fifty day moving average price of $89.71 and a 200-day moving average price of $85.26.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the prior year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,045 shares of company stock worth $457,749 over the last ninety days. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.